Back to Search
Start Over
What proceduralists need to know about emicizumab for patients with hemophilia A.
- Source :
-
Proceedings (Baylor University. Medical Center) [Proc (Bayl Univ Med Cent)] 2020 Dec 14; Vol. 34 (2), pp. 334-335. Date of Electronic Publication: 2020 Dec 14. - Publication Year :
- 2020
-
Abstract
- Competing Interests: Dr. Pivalizza has no conflicts of interested to declare. Dr. Escobar has participated in advisory committees and/or consultancy for: Genentech, National Hemophilia Foundation, Novo Nordisk, Pfizer, Sanofi, Takeda, Biomarin, CSL Behring, Kedrion, and the US Food and Drug Administration, none of which are relevant for this submission.
Details
- Language :
- English
- ISSN :
- 0899-8280
- Volume :
- 34
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Proceedings (Baylor University. Medical Center)
- Publication Type :
- Academic Journal
- Accession number :
- 33678983
- Full Text :
- https://doi.org/10.1080/08998280.2020.1851628